Delta-8-THC produced tolerance, dependence, and abuse-like effects similar to delta-9-THC in mice

A controlled study in mice found delta-8-THC produces tolerance, physical dependence, and discriminative stimulus effects qualitatively similar to delta-9-THC, challenging marketing claims that it is a milder alternative.

Vanegas, S O et al.·Drug and alcohol dependence·2022·Moderate EvidenceAnimal StudyAnimal Study
RTHC-04273Animal StudyModerate Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Delta-8-THC produced cannabimimetic effects (catalepsy, antinociception, hypothermia, immobility) at doses above 12.5 mg/kg, all blocked by the CB1 antagonist rimonabant. Repeated administration produced tolerance and cross-tolerance to WIN 55,212-2. Rimonabant-precipitated withdrawal produced physical dependence signs. Delta-8-THC produced delta-9-THC-like discriminative stimulus effects in both sexes.

Key Numbers

Delta-8-THC active at doses above 12.5 mg/kg. Repeated 50 mg/kg produced tolerance and cross-tolerance. Withdrawal signs observed after 10 mg/kg BID for 6 days. Both male and female mice showed delta-9-THC-like discriminative effects.

How They Did This

Adult male and female C57BL/6J mice were tested in the tetrad battery (catalepsy, antinociception, hypothermia, immobility) after acute delta-8-THC. Tolerance assessed after repeated dosing. Physical dependence assessed via rimonabant-precipitated withdrawal. Drug discrimination tested for abuse potential.

Why This Research Matters

Delta-8-THC is marketed as a legal, milder alternative to delta-9-THC. This study provides direct evidence that it produces the same types of tolerance, dependence, and abuse liability, undercutting those marketing claims.

The Bigger Picture

The delta-8-THC market has exploded due to legal loopholes. This is one of the first rigorous studies to assess its dependence and abuse potential, providing evidence that regulators and consumers should take seriously.

What This Study Doesn't Tell Us

Animal study, so doses and effects may not directly translate to humans. The doses required for effects were higher than for delta-9-THC, consistent with lower potency. Does not address the full range of subjective human experiences.

Questions This Raises

  • ?Is delta-8-THC truly less potent than delta-9 in humans, or just in mice?
  • ?Should delta-8-THC be subject to the same regulations as delta-9?
  • ?Do the tolerance and dependence findings apply to the lower doses typically consumed by humans?

Trust & Context

Key Stat:
Delta-8 produced delta-9-like dependence and abuse liability in both sexes
Evidence Grade:
Moderate: rigorous pharmacological methods in both sexes, but animal study only.
Study Age:
Published in 2022.
Original Title:
Assessment of dependence potential and abuse liability of Δ8-tetrahydrocannabinol in mice.
Published In:
Drug and alcohol dependence, 240, 109640 (2022)
Database ID:
RTHC-04273

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Is delta-8-THC really milder than delta-9?

It required higher doses to produce effects in mice, suggesting lower potency. However, it produced the same types of tolerance, physical dependence, and abuse liability, meaning "milder" may be misleading.

Can you become dependent on delta-8-THC?

In mice, yes. Repeated delta-8-THC administration produced physical dependence, with withdrawal signs emerging when a CB1 receptor blocker was given.

Why is delta-8 legally available?

Delta-8-THC can be derived from hemp-sourced CBD, which some interpret as making it legal under the 2018 Farm Bill. However, its pharmacological similarity to delta-9-THC raises regulatory questions.

Read More on RethinkTHC

Cite This Study

RTHC-04273·https://rethinkthc.com/research/RTHC-04273

APA

Vanegas, S O; Reck, A M; Rodriguez, C E; Marusich, J A; Yassin, O; Sotzing, G; Wiley, J L; Kinsey, S G. (2022). Assessment of dependence potential and abuse liability of Δ8-tetrahydrocannabinol in mice.. Drug and alcohol dependence, 240, 109640. https://doi.org/10.1016/j.drugalcdep.2022.109640

MLA

Vanegas, S O, et al. "Assessment of dependence potential and abuse liability of Δ8-tetrahydrocannabinol in mice.." Drug and alcohol dependence, 2022. https://doi.org/10.1016/j.drugalcdep.2022.109640

RethinkTHC

RethinkTHC Research Database. "Assessment of dependence potential and abuse liability of Δ8..." RTHC-04273. Retrieved from https://rethinkthc.com/research/vanegas-2022-assessment-of-dependence-potential

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.